Showing results (21-30 of 265) with videos related to
Sort By:
Pageof 27
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 24, 2022
Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or UstekinumabAndres J Yarur, Dermot McGovern, Maria T Abreu, et al.Antimicrobial Agents and Chemotherapy|May 1, 2013
Human monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytesHon Wai Koon, David Q Shih, Tressia C Hing, et al.Inflammatory Bowel Diseases|November 15, 2014
Molecular patterns in human ulcerative colitis and correlation with response to infliximabBrendan Halloran, Jessica Chang, David Q Shih, et al.Immunological Reviews|July 29, 2005
Defects in mucosal immunity leading to ulcerative colitisStephan R Targan, Loren C KarpAdvances in Pharmacology (San Diego, Calif.)|November 9, 2024
TL1A: A model for a precision medicine approach in the treatment of Crohn's disease and ulcerative colitisJanine M Bilsborough, Stephan R TarganNature Reviews. Gastroenterology & Hepatology|February 6, 2010
Future biologic targets for IBD: potentials and pitfallsGil Y Melmed, Stephan R TarganGastroenterology|May 23, 2002
Biologic therapy of inflammatory bowel diseaseWilliam J Sandborn, Stephan R TarganGastroenterology|May 3, 2011
Future therapeutic approaches for inflammatory bowel diseasesScott E Plevy, Stephan R TarganCurrent Opinion in Gastroenterology|June 5, 2007
Inflammatory bowel disease diagnosis, evaluation and classification: state-of-the art approachStephan R Targan, Loren C KarpExpert Review of Gastroenterology & Hepatology|November 5, 2014
Should biologic agents be stopped before surgery for inflammatory bowel disease?Karen Zaghiyan, Dermot McGovern, Phillip FleshnerPageof 27